Literature DB >> 15964852

Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif.

Hongyan Zhu1, Linghu Nie, Carl G Maki.   

Abstract

p21 is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors that includes p21, p27, and p57. Recent studies have suggested that Cdk2 activity may promote p21 degradation through a pathway similar to that for p27, although the mechanism by which this occurs has not been clarified. In the current report, co-expression with cyclin E and Cdk2 stabilized p21 in a manner that required the CDK-binding site of p21 and a cyclin-binding site (cy1) located in the p21 N terminus. Strikingly, however, a kinase-dead Cdk2 mutant stabilized p21 to a greater extent than did wild-type Cdk2, consistent with the notion that Cdk2 activity can destabilize p21. The ability of wild-type Cdk2 to destabilize p21 required a potential Cdk2 phosphorylation site in p21 at serine 130 and an intact cyclin-binding motif (cy2) in the p21 C terminus. Finally, p21 was phosphorylated by Cdk2 at Ser-130 in vitro, and this ability of Cdk2 to phosphorylate p21 was dependent, in large part, on the presence of cy2. These results support a model in which active Cdk2 destabilizes p21 via the cy2 cyclin-binding motif and p21 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964852     DOI: 10.1074/jbc.M407352200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase.

Authors:  Virginia Amador; Sheng Ge; Patricia G Santamaría; Daniele Guardavaccaro; Michele Pagano
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

2.  Flipping the switch from g1 to s phase with e3 ubiquitin ligases.

Authors:  Lindsay F Rizzardi; Jeanette Gowen Cook
Journal:  Genes Cancer       Date:  2012-11

Review 3.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

4.  Degradation of p21Cip1 through anaphase-promoting complex/cyclosome and its activator Cdc20 (APC/CCdc20) ubiquitin ligase complex-mediated ubiquitylation is inhibited by cyclin-dependent kinase 2 in cardiomyocytes.

Authors:  Kazuhiko Yamada; Mimi Tamamori-Adachi; Ikuko Goto; Masayoshi Iizuka; Takashi Yasukawa; Teijiro Aso; Tomoki Okazaki; Shigetaka Kitajima
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

Review 5.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

6.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation.

Authors:  Ji Young Lee; Su Jin Yu; Yun Gyu Park; Joon Kim; Jeongwon Sohn
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 8.  The cell cycle and acute kidney injury.

Authors:  Peter M Price; Robert L Safirstein; Judit Megyesi
Journal:  Kidney Int       Date:  2009-06-17       Impact factor: 10.612

9.  PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex.

Authors:  Tarek Abbas; Uma Sivaprasad; Kenta Terai; Virginia Amador; Michele Pagano; Anindya Dutta
Journal:  Genes Dev       Date:  2008-09-15       Impact factor: 11.361

Review 10.  Cell cycle regulation by the intrinsically disordered proteins p21 and p27.

Authors:  Mi-Kyung Yoon; Diana M Mitrea; Li Ou; Richard W Kriwacki
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.